These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 37007546)
1. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma. Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546 [TBL] [Abstract][Full Text] [Related]
2. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs. Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187 [TBL] [Abstract][Full Text] [Related]
3. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients. Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212 [TBL] [Abstract][Full Text] [Related]
4. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454 [TBL] [Abstract][Full Text] [Related]
5. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma. Ma C; Li F; Gu Z; Yang Y; Qi Y Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938 [No Abstract] [Full Text] [Related]
6. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer. Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429 [TBL] [Abstract][Full Text] [Related]
7. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma. Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612 [TBL] [Abstract][Full Text] [Related]
8. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma. Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235 [TBL] [Abstract][Full Text] [Related]
10. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer. Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405 [TBL] [Abstract][Full Text] [Related]
11. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
12. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma. Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S Front Genet; 2022; 13():862741. PubMed ID: 35368663 [No Abstract] [Full Text] [Related]
13. Construction and validation of a novel cuproptosis-related long noncoding RNA signature for predicting the outcome of prostate cancer. Jiang S; Li Z; Dou R; Lin Z; Zhang J; Zhang W; Chen Z; Shen X; Ji J; Qu M; Wang Y; Li M; Gao X Front Genet; 2022; 13():976850. PubMed ID: 36561322 [No Abstract] [Full Text] [Related]
14. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. Wang F; Lin H; Su Q; Li C World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740 [TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Xu M; Mu J; Wang J; Zhou Q; Wang J Front Oncol; 2022; 12():961213. PubMed ID: 35965536 [TBL] [Abstract][Full Text] [Related]
16. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma. Wang X; Jing H; Li H Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935 [TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related long non-coding ribonucleic acid signature as a novel prognosis model for colon cancer. Xu R; Wu X; Du A; Zhao Q; Huang H Am J Cancer Res; 2022; 12(11):5241-5254. PubMed ID: 36504883 [TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma. Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979 [TBL] [Abstract][Full Text] [Related]
19. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response. Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328 [TBL] [Abstract][Full Text] [Related]
20. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]